Trial Profile
A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With Larazotide Acetate (AT-1001)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Larazotide (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors Alba Therapeutics
- 12 Dec 2014 New trial record